Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pre-procedural levels of C-reactive protein (mg/L) and calprotectin (mg/L)
Timeframe: At hospital admission, before TAVI procedure
Pre-procedural level of interleukin-6 (ng/L)
Timeframe: At hospital admission, before TAVI procedure
Pre-procedural levels of procalcitonin (µg/L) and ferritin (µg/L)
Timeframe: At hospital admission, before TAVI procedure
Pre-procedural level of transforming growth factor-β1(pg/ml)
Timeframe: At hospital admission, before TAVI procedure
Pre-procedural level of lactate-dehydrogenase (U/I)
Timeframe: At hospital admission, before TAVI procedure
Pre-procedural C-reactive protein to albumin ratio and index of systemic immuno-inflammation values
Timeframe: At hospital admission, before TAVI procedure